Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · Real-Time Price · USD
5.31
-0.64 (-10.76%)
At close: Feb 21, 2025, 4:00 PM
5.21
-0.10 (-1.86%)
After-hours: Feb 21, 2025, 6:02 PM EST
CPIX Employees
Cumberland Pharmaceuticals had 91 employees as of December 31, 2023. The number of employees increased by 6 or 7.06% compared to the previous year.
Employees
91
Change (1Y)
6
Growth (1Y)
7.06%
Revenue / Employee
$404,236
Profits / Employee
-$119,455
Market Cap
74.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CPIX News
- 5 days ago - VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA - PRNewsWire
- 18 days ago - Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Benzinga
- 19 days ago - Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PRNewsWire
- 2 months ago - Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? - Benzinga
- 2 months ago - FDA APPROVES ACETADOTE® sNDA - PRNewsWire
- 3 months ago - Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update - PRNewsWire
- 3 months ago - CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY - PRNewsWire